Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review

References

• American Cancer Society: cancer Facts and Figures 2020.https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 2021 Jan 3.
   Google Scholar
• Lung Cancer - Non-Small Cell - Statistics. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Published May 28, 2020. Accessed 2020 Dec 12.
   Google Scholar
• Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16(6):653–660.
   PubMed Web of Science ®Google Scholar
• Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(5):553–559.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243–1260. .
   PubMed Web of Science ®Google Scholar
• Referenced with permission from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V2.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed 2020 Dec 30. To view the most recent and complete version of the guidelines, go online to NCCN.org.
   Google Scholar
• Targeted Drug Therapy for Non-Small Cell Lung Cancer. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html. Updated December 22, 2020. Accessed 2020 Dec 30.
   Google Scholar
• Immunotherapy for Non-Small Cell Lung Cancer. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/immunotherapy.html. Updated May 22, 2020. Accessed 2020 Dec 30.
   Google Scholar
• Lange A, Prenzler A, Frank M, et al. A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC). BMC Pulm Med. 2014;14:192.
   PubMed Web of Science ®Google Scholar
• Bongers ML, Coupe VMH, Jansma EP, et al., Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 2012; 30(1): 17–34.
   PubMed Web of Science ®Google Scholar
• Jakel A, Plested M, Dharamshi K, et al., A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Appl Health Econ Health Policy. 2013; 11(1): 27–43.
   PubMedGoogle Scholar
• Consumer Price Index. U.S. Bureau of Labor Statistics. www.bls.gov/cpi/. Accessed 2020 Dec 30.
   Google Scholar
• Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003 Jan-Feb 9;(1)53–61.
   PubMedGoogle Scholar
• Georgieva M. Da Silveira Nogueira Lima JP, Aguiar P Jr, et al. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer. 2018;124:248–254.
   PubMed Web of Science ®Google Scholar
• Huang M, Lou Y, Pellissier J, et al., Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United StatesPharmacoEconomics. 2017 Aug;358:831–844.
   Google Scholar
• Huang M, Lopes GL, Insinga RP, et al. Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA. Immunotherapy. 2019 Dec;11(17):1463–1478.
   PubMed Web of Science ®Google Scholar
• She L, Hu H, Liao M, et al. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung Cancer. 2019;138:88–94.
   PubMed Web of Science ®Google Scholar
• Weng X, Luo S, Lin S, et al., Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. Oncol Res. 2020; 28(2): 117–125.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al., Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018; 21(12): 1191–1205.
   PubMed Web of Science ®Google Scholar
• Insinga RP, Vanness DJ, Feliciano JL, et al., Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019; 35(7): 1241–1256.
   PubMed Web of Science ®Google Scholar
• Criss SD, Mooradian MJ, Watson TR, et al., Cost-effectiveness of atezolizumab combination therapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer in the United States. JAMA Network Open. 2019;2(9): e1911952.
   PubMed Web of Science ®Google Scholar
• Criss SD, Palazzo L, Watson TR, et al., Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. PLoS One. 2020; 15(1): e0228288.
   PubMed Web of Science ®Google Scholar
• Zeng X, Wan X, Peng L, et al., Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 2019;9(12): e031019.
   PubMed Web of Science ®Google Scholar
• Huang M, Lou Y, Pellissier J, et al., Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017;20(2): 140–150.
   PubMed Web of Science ®Google Scholar
• Gilden DM, Kubisiak JM, Pohl GM, et al., Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017;20(2): 151–161.
   PubMed Web of Science ®Google Scholar
• Goulart B, Ramsey S, A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer, Value Health, 2011 Sep-Oct;146:836–845.
   PubMed Web of Science ®Google Scholar
• Klein R, Muehlenbein C, Liepa AM, et al., Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009;4(11): 1404–1414.
   PubMed Web of Science ®Google Scholar
• Wan X, Luo X, Tan C, et al., First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: a United States-based cost-effectiveness analysis. Cancer. 2019;125(20): 3526–3534.
   PubMed Web of Science ®Google Scholar
• Shah M, Winfree KB, Peterson P, et al., Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. Lung Cancer. 2013;82(1): 121–127.
   PubMed Web of Science ®Google Scholar
• Klein R, Wielage R, Muehlenbein C, et al., Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8): 1263–1272.
   PubMed Web of Science ®Google Scholar
• Kumar G, Woods B, Hess LM, et al., Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer. 2015;89(3): 294–300.
   PubMed Web of Science ®Google Scholar
• Ting J, Ho P T, Xiang P, et al., Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6): 774–782.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Reyes C, Oestriecher N, et al., Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer. 2008;61(3): 405–415.
   PubMed Web of Science ®Google Scholar
• Aguiar PN, Haaland B, Park W, et al., Cost-effectiveness of osimertinib in the first-line treatment of patients with EGFR-mutated advanced non–small cell lung cancer. JAMA Oncol. 2019;4(8): 1080–1084.
   Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, Cost-effectiveness of osimertinib for EGFR mutation-positive non-small cell lung cancer after progression following first-line EGFR TKI therapy, J Thorac Oncol, 2018;132:184–193.
   PubMed Web of Science ®Google Scholar
• Wu B, Gu X, Zhang Q, et al. Cost-Effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24(3):349–357. .
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Canestaro W, Ravelo A, et al., The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. J Med Econ. 2017; 20(7): 671–677.
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Suh K, Orfanos P, et al., Cost effectiveness of alectinib vs. crizotinib in first-line anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Pharmacoeconomics. 2018; 36(4): 495–504.
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Mutebi A, Han S, et al. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. J Med Econ. 2018;21(6):577–586.
   PubMed Web of Science ®Google Scholar
• Criss SD, Mooradian MJ, Sheehan DF, et al., Cost-effectiveness and budgetary consequence analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the US health care system. JAMA Oncol. 2019; 5(3): 358–365.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al., Necitumumab in metastatic squamous cell lung cancer establishing a value-based cost. JAMA Oncol. 2015; 1(9): 1293–1300.
   PubMed Web of Science ®Google Scholar
• How We Diagnose Non-Small Cell Lung Cancer. Dana-Farber Cancer Institute. https://www.dana-farber.org/non-small-cell-lung-cancer/diagnosis/. Accessed 2021 Jan 31.
   Google Scholar
• Vakil E Cost-effectiveness of CT-guided transthoracic biopsy and diagnostic bronchoscopy with and without rapid onsite evaluation for suspected lung cancer. Poster presented at: CHEST Annual Meeting; October 21, 2019; New Orleans, LA. USA.
   Google Scholar
• Shim HS, Choi YL, Kim L, et al. Molecular Testing of Lung Cancers. J Pathol Transl Med. 2017;51(3):242–254.
   PubMed Web of Science ®Google Scholar
• Revelo AE, Martin A, Velasquez R, et al. Liquid biopsy for lung cancers: an update on recent developments. Ann Transl Med. 2019;7(15):349.
   PubMed Web of Science ®Google Scholar
• Pennell NA, Mutebi A, Zhou ZY, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. J Clin Oncol. 2019;3:1–9.
   Google Scholar